The effect of atrovastatin on the ovarian arterial blood flow and serum androgen level in PCOS patient

Akbari, M. and Almasi, A. and Naderi, Z. and Kouhpayezadeh, J. and Pourali, R. and Hossinzadeh, Z. (2016) The effect of atrovastatin on the ovarian arterial blood flow and serum androgen level in PCOS patient. Biomedical and Pharmacology Journal, 9 (3). pp. 1041-1048.

[img] Text
The effect of atrovastatin on the ovarian arterial blood flow and serum androgen level in PCOS patient.pdf

Download (48kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Various researches have been conducted over the recent years on the therapeutic effects of statins on the metabolic and hyper-androgenic state of the patients suffering from PCOS. The present research seeks to evaluate the treatment with atorvastatin and its effect on the lipid profile level, serum androgen status and morphology and blood flow of polycystic ovaries. A double blind clinical trial was designed for this research where the women with PCOS resorting to the gynecology clinic of Firouzgar Hospital were randomly divided into two groups: case and Control. Early at the beginning of the research, variables such as body mass, lipid profile, blood androgen level, fasting blood Sugar, size of the ovary, and resistance of the stromal artery of ovary were studied. For a period of 6 weeks, one group was given with a daily dose of 40 mg atorvastatin, while the other group just received placebo. All the variables were studied once again after 6 weeks and the results were analyzed using SPSS v.16. The case group included 20 patients suffering from PCOS who received atorvastatin, while there were 20 patients with PCOS in the witness group who just received placebo. The average ages in the atorvastatin and placebo groups were 27.7 ± 3.41 and 30.9 ± 4.8 years old respectively. A significant difference was observed between the two groups in terms of changes in the average cholesterol and LDL levels before and after the intervention. This reduction was more significant in the atorvastatin group. After prescription of atorvastatin, the level of Androstenedione had decreased significantly in treatment group. A statistically significant reduction was observed in the size of left and right ovaries in the group receiving atorvastatin. No significant changes were observed in the size of the ovaries in the group receiving placebo. The average arterial resistance level of left and right ovaries before and after intervention in atorvastatin group exhibited a significant reduction. Having discarded the confounding effect of RI, this difference with the witness group was statistically significant. Keeping in mind the effects of atorvastatin such as improving the lipid profile status and reduction of androstenedione among those with PCOS, it can be used as an auxiliary treatment to control symptoms and long-term side effects among patients. Considering the shrinkage of ovary size and enhancement of blood flow to PCOS ovary, future researches can focus on effectiveness of statins in improving the ovulation status of performance of PCO ovaries.

Item Type: Article
Additional Information: cited By 0
Subjects: WP Gynecology
QV Pharmacology
Depositing User: eprints admin
Date Deposited: 02 Jul 2018 09:56
Last Modified: 12 Nov 2019 11:05
URI: http://eprints.iums.ac.ir/id/eprint/4301

Actions (login required)

View Item View Item